← All trials
NCT05425745
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Jul 30, 2024
- First posted
- Jun 21, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NewAmsterdam PharmaLead sponsor
- NewAmsterdam PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.